RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.